BACKGROUND: Fatigue among patients with cancer is prevalent, disabling, and treatable. While fatigue management guidelines have been in place for a decade, their use remains unclear. METHODS: We surveyed 160 patients with stage IV lung (40), breast (40), colon (40), and prostate (40) cancer who reported moderate to severe fatigue (i.e., >5 of 10 on an 11-point numerical rating scale). Participants were queried about receipt of treatments in fatigue management domains emphasized in the National Comprehensive Cancer Network guidelines: general management strategies, activity enhancement, psychosocial strategies, and pharmaceuticals. RESULTS: The cohort was half male, had a mean age of 67, and reported an average fatigue rating of 6.4. Participants reported treatment or receipt of specific guidance in the fatigue management domains as follows: general management strategies 16.8 %, activity enhancement 11.9 %, psychosocial strategies 9.9 %, and pharmaceuticals 37.3 %. Fatigue >7 of 10 increased the likelihood of instruction in activity enhancement but no other domain. CONCLUSION: The low rates of guideline-congruent treatment reported here are concerning, particularly as better validated behavioral treatments were the least prescribed.
BACKGROUND: Fatigue among patients with cancer is prevalent, disabling, and treatable. While fatigue management guidelines have been in place for a decade, their use remains unclear. METHODS: We surveyed 160 patients with stage IV lung (40), breast (40), colon (40), and prostate (40) cancer who reported moderate to severe fatigue (i.e., >5 of 10 on an 11-point numerical rating scale). Participants were queried about receipt of treatments in fatigue management domains emphasized in the National Comprehensive Cancer Network guidelines: general management strategies, activity enhancement, psychosocial strategies, and pharmaceuticals. RESULTS: The cohort was half male, had a mean age of 67, and reported an average fatigue rating of 6.4. Participants reported treatment or receipt of specific guidance in the fatigue management domains as follows: general management strategies 16.8 %, activity enhancement 11.9 %, psychosocial strategies 9.9 %, and pharmaceuticals 37.3 %. Fatigue >7 of 10 increased the likelihood of instruction in activity enhancement but no other domain. CONCLUSION: The low rates of guideline-congruent treatment reported here are concerning, particularly as better validated behavioral treatments were the least prescribed.
Authors: Amy P Abernethy; Asif Ahmad; S Yousuf Zafar; Jane L Wheeler; Jennifer Barsky Reese; H Kim Lyerly Journal: Med Care Date: 2010-06 Impact factor: 2.983
Authors: Bernardine M Pinto; Georita M Frierson; Carolyn Rabin; Joseph J Trunzo; Bess H Marcus Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: Victoria Mock; Constantine Frangakis; Nancy E Davidson; Mary E Ropka; Mary Pickett; Barbara Poniatowski; Kerry J Stewart; Lane Cameron; Kristin Zawacki; Laura J Podewils; Gary Cohen; Ruth McCorkle Journal: Psychooncology Date: 2005-06 Impact factor: 3.894
Authors: C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya Journal: N Engl J Med Date: 1994-03-03 Impact factor: 91.245
Authors: J F Lehmann; J A DeLisa; C G Warren; B J deLateur; P L Bryant; C G Nicholson Journal: Arch Phys Med Rehabil Date: 1978-09 Impact factor: 3.966
Authors: Sarah K Rosenbloom; David E Victorson; Elizabeth A Hahn; Amy H Peterman; David Cella Journal: Psychooncology Date: 2007-12 Impact factor: 3.894
Authors: Yong Chol Kwon; Young Ho Yun; Ki Heon Lee; Ki Young Son; Sang Min Park; Yoon Jung Chang; Xin Shelley Wang; Tito R Mendoza; Charles S Cleeland Journal: Oncology Date: 2007-03-05 Impact factor: 2.935
Authors: Yoon Jung Chang; Jung Suk Lee; Chang Geol Lee; Won Sup Lee; Keun Seok Lee; Soo-Mee Bang; Xin Shelley Wang; Tito R Mendoza; Charles S Cleeland; Young Ho Yun Journal: Support Care Cancer Date: 2007-07 Impact factor: 3.359
Authors: Andrea L Cheville; Naveen S Murthy; Jeffrey R Basford; Peter S Rose; Kenny Tran; Thomas P Pittelkow; Michael D Ringler Journal: Arch Phys Med Rehabil Date: 2015-10-03 Impact factor: 3.966
Authors: Isrid Sturm; Johanna Baak; Benjamin Storek; Annette Traore; Peter Thuss-Patience Journal: Support Care Cancer Date: 2014-03-27 Impact factor: 3.603
Authors: Andrea L Cheville; Lori Rhudy; Jeffrey R Basford; Joan M Griffin; Ann Marie Flores Journal: Arch Phys Med Rehabil Date: 2016-08-31 Impact factor: 3.966
Authors: Lila J Finney Rutten; Kathryn J Ruddy; Linda L Chlan; Joan M Griffin; Jeph Herrin; Aaron L Leppin; Deirdre R Pachman; Jennifer L Ridgeway; Parvez A Rahman; Curtis B Storlie; Patrick M Wilson; Andrea L Cheville Journal: Trials Date: 2020-06-05 Impact factor: 2.279
Authors: Grant A Wintheiser; Kathryn J Ruddy; Jeph Herrin; Parvez A Rahman; Deirdre R Pachman; Aaron L Leppin; Lila J Finney Rutten; Minji K Lee; Joan M Griffin; Cindy Tofthagen; Linda L Chlan; Jennifer L Ridgeway; Sandra A Mitchell; Andrea L Cheville Journal: J Natl Cancer Inst Date: 2022-03-08 Impact factor: 13.506